A practical guide to psilocybin research

Find the resource that fits your question

Psilocybin, psilocin and the scope of this database

Psilocybin is converted in the body to psilocin. Literature may therefore discuss the administered compound, the active compound, or both. The NCCIH overview provides a public introduction to the compounds and research context.

This database combines bibliographic records from multiple sources. It includes clinical, preclinical and other relevant literature, rather than only treatment trials. Source coverage, retrieval and relevance screening have limitations; inclusion does not certify study quality. Visit methods and provenance before using the corpus as the basis for a review.

For a research search, try both compound names and the condition or mechanism of interest. Check status and design filters, then follow the original source. Broad matches can help discovery, but a systematic review requires a documented search strategy, screening criteria and a reproducible selection process beyond this interface.

Seven questions to ask when reading a psilocybin study

1. Who was studied? Record diagnosis, recruitment setting, eligibility and exclusions. Findings in selected volunteers may not transfer to another population.
2. What was compared? Identify the control, dose schedule and psychological support in each group. An open-label or wait-list design answers a different question from an active-comparator randomized trial.
3. What was the primary outcome? Separate prespecified primary endpoints from secondary measures and exploratory analyses. A positive secondary finding does not replace an unsuccessful primary comparison.
4. How large and uncertain was the effect? Keep the scale, units, group difference and confidence interval together. Statistical significance alone does not establish clinical importance.
5. How long did follow-up last? A result at two weeks is not evidence of a year-long benefit. Look for missing observations, withdrawals and the population included in each analysis.
6. Could expectations influence results? Participants or assessors may infer allocation from noticeable subjective effects. Check blinding assessments and the report's discussion of this limitation.
7. What happened beyond the efficacy score? Read adverse events, serious events, discontinuations, funding, conflicts and corrections. Small samples can miss uncommon harms.

Apply the checklist to the depression comparison or alcohol study comparison. These selections demonstrate interpretation and do not replace a formal evidence synthesis.

Research terms used across the tracker

Randomized controlled trial

Assignment to study groups uses a random process. Randomization supports comparison, but still requires scrutiny of blinding, missing data and the analysis plan.

Open-label study

Participants or investigators know the intervention. Observed change can help establish feasibility and generate hypotheses; without an appropriate comparator it does not isolate a treatment effect.

Preprint

A manuscript shared before journal peer review. Check for a later version, correction or published article before relying on its findings.

Protocol or registration

A description of planned methods, eligibility and outcomes. It is not evidence that the intervention worked. Registration records can later link to posted results or publications.

Review and meta-analysis

A review synthesizes prior work; a meta-analysis statistically combines estimates. Conclusions depend on selection, study quality and whether the pooled studies address sufficiently comparable questions.

Confidence interval

An interval expressing uncertainty under the analysis assumptions. Examine its range alongside the point estimate and outcome units.

Publication count

A count of indexed records, not necessarily unique experiments or participants. Multiple papers may describe one study; registration records and published reports are distinct.

Tracker study labels and topic tags are discovery aids. They are not independently verified evidence grades or clinical diagnoses. See the editorial policy for classification and manual review.

Keep discovery, citation and analysis reproducible

When exporting a selection, record your query, filters and retrieval date. For an analysis of the whole corpus, preserve the downloaded data and checksum, document the source version and explain how you treated preprints, registrations and missing dates. Use a fixed dataset version when another reader needs to reproduce the same result.

The dataset guide explains citation and download options. The October brief supplies frozen analytical input and scripts. The R toolkit supports bibliometric exploration; inspect coverage and matching limitations before interpreting its network.

Public exports provide rights-safe bibliographic metadata and original derived annotations. An abstract-availability indicator does not grant permission to redistribute the underlying text. Follow the original source for full text and its licence.

Sources, accountability and limits

This is an original guide to using the tracker and interpreting research designs, reviewed on 7 October 2026. It is educational and does not provide individualized treatment advice or claim independent clinical review.

• NCCIH: psilocybin research and safety context
• ClinicalTrials.gov: how to read a study record
• NIH: clinical research basics
• Tracker authorship, corrections and source policy

New studies can change the evidence. Consult current source records and the live database alongside these dated guides. Reproducibility and explicit uncertainty remain necessary even when a finding is promising.